Urine epidermal growth factor as a biomarker for kidney function recovery and prognosis in glomerulonephritis with severe kidney function impairment
Journal
Journal of Nephrology
ISSN
1724-6059
Publisher
Springer
Date Issued
2024
Author(s)
Hernández-Andrade, Adriana
Nordmann-Gomes, Alberto
Juárez-Cuevas, Bernardo
Zavala-Miranda, Maria Fernanda
Cruz, Cristino
Mejía-Vilet, Juan M.
Type
text::journal::journal article
Abstract
Background: Prognostication in glomerulonephritis with severe kidney function impairment is critical for evaluating the benefit-to-risk ratio of immunosuppression. We hypothesized that the urine biomarker epidermal growth factor (EGF) could have good discrimination power to identify subjects who might ultimately recover kidney function. Methods: We included 82 subjects with glomerulonephritis and severe kidney function impairment at admission (estimated glomerular filtration rate [eGFR] ≤ 30 mL/min/1.73m2): 58 with lupus nephritis (LN) and 24 with ANCA-associated vasculitis (AAV). Thirty-five subjects required kidney replacement therapy (KRT) at presentation. Urine epidermal growth factor was measured and corrected by urine creatinine (uEGF/Cr) and the population was analyzed by uEGF/Cr tertiles. The primary outcome was time to recovery of eGFR ≥ 30 mL/min/1.73m2 and time to recovery of kidney function with dialysis independence in those with initial KRT. ©The authors ©Journal of Nephrology © Springer.
License
Acceso Restringido
How to cite
Hernández-Andrade, A., Nordmann-Gomes, A., Juárez-Cuevas, B. et al. Urine epidermal growth factor as a biomarker for kidney function recovery and prognosis in glomerulonephritis with severe kidney function impairment. J Nephrol (2024). https://doi.org/10.1007/s40620-024-02068-6